Lenetix Reports Submission of Clinical Data for the Commercial Launch of Non-Invasive Prenatal Rhesus D Incompatibility Test
02-Jul-2007
Lenetix's RhD application of Sequenom's proprietary Fetal Nucleic Acid Technology detects a fetus' RhD status from the mother's blood sample without invasive procedures that typically pose risk to the health of the mother and baby in utero.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.